This systematic review summarizes pharmacogenetic studies on antidepressant response
and side effects. Out of the 17 genes we reviewed, 8 genes were entered into the meta …

Personalized medicine—the adaptation of therapies based on an individual's genetic and
molecular profile—is one of the most promising aspects of modern medicine. The …

A number of candidate gene studies focused on major depression (MD) and antidepressant
(AD) efficacy have been carried out, but results mainly remain inconclusive. We performed a …

In spite of promising preclinical results there is a decreasing number of new registered
medications in major depression. The main reason behind this fact is the lack of confirmation …

Major Depressive Disorder (MDD) is a prevalent illness that is frequently associated with
significant disability, morbidity and mortality. Despite the development and availability of …

Major depressive disorder (MDD) is an emergent cause of personal and socio‐economic
burden, both for the high prevalence of the disorder and the unsatisfying response rate of …

Up to 60% of depressed patients do not respond completely to antidepressants (ADs) and
up to 30% do not respond at all. Genetic factors contribute for about 50% of the AD …

Genes that regulate the serotonin signalling system are potential targets for research in the
aetiology of mood disorders and also in the treatment response of serotonin reuptake …

While antidepressant pharmacotherapy is an effective treatment of depression, it is still
hampered by the slow onset of appreciable clinical improvement and a series of side effects …

Major depressive disorder (MDD) is characterized by mood, vegetative, cognitive, and even
psychotic symptoms and signs that can cause substantial impairments in quality of life and …